CRDF Q1 2024 Earnings — Cardiff Oncology, Inc. Revenue & Financial Results | Market Cap Arena

CRDFCardiff Oncology, Inc.

$139M

Q1 2024 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$205,000+147.0% YoY

Gross Profit

$103,00050.2% margin

Operating Income

-$11M-5333.2% margin

Net Income

-$10M-4883.4% margin

EPS (Diluted)

$-0.22

QoQ Revenue Growth

+31.4%

Cash Flow

Operating Cash Flow

-$8M

Free Cash Flow

-$8M

Stock-Based Comp.

$1M

Balance Sheet

Total Assets

$74M

Total Liabilities

$13M

Stockholders' Equity

$61M

Cash & Equivalents

$19M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$205,000	$83,000	+147.0%
Gross Profit	$103,000	$83,000	+24.1%
Operating Income	-$11M	-$12M	+9.3%
Net Income	-$10M	-$11M	+10.8%